Gary Fischer
Analyst · Craig-Hallum
Thank you, Leslie, and good afternoon to everyone. Revenue for the fourth quarter of 2023 was $20.4 million, up from $17.4 million in the third quarter of 2023 and down from $26.8 million in the fourth quarter of 2022. To break down our Q4 '23 revenue for you by product category, indium phosphide increased sequentially to $5.4 million reflecting a stabilizing market with continued improvement in artificial intelligence, ponds and data center applications. Gallium arsenide also grew to $6.0 million with excess inventory largely worked down and certain applications showing improvement. Germanium substrates were $1.1 million, down slightly from the prior quarter. Finally, revenue from our consolidated raw material joint venture companies in Q4 was $7.9 million. In the fourth quarter of 2023, revenue from Asia Pacific was 77%. Europe was 16%, and North America was 7%. The top 5 customers generated approximately 28% of total revenue and no customer was over the 10% level. Non-GAAP gross margin in the fourth quarter was 23.2% compared with 11.3% in Q3 of 2023 and 32.5% in Q4 of 2022. For those who prefer to track results on a GAAP basis, gross margin in the fourth quarter was 22.6% compared with 10.7% in Q3 of 2023 and 32.1% in Q4 of 2022. The primary drivers of the sequential improvement in our corporate gross margin in Q4 were higher additional volume, product mix and improved gross margins at both JinMei and BoYu. Beyond the near term, we remain confident that we can get back to the mid-30% range as the environment strengthens through higher overall volume, more favorable product mix and the benefits of our recycling programs, along with continued efficiency improvements throughout our business. Moving to operating expenses. The reduction in overall revenue, we have maintained spending discipline in our operating expenses to align with the current environment. Total non-GAAP operating expense in Q4 was $7.5 million, down from $7.8 million in Q3 of 2023 and down from $8.9 million in Q4 of 2022. On a GAAP basis, total operating expense in Q4 of 2023 was $8.2 million, down from $8.6 million in Q3 and down from $9.6 million in Q4 of 2022. Our non-GAAP operating income for the fourth quarter of 2023 was a loss of $2.7 million compared with a non-GAAP operating loss in Q3 of 2023 of $5.8 million and a non-GAAP operating loss of $256,000 in Q4 of 2022. For reference, our GAAP operating line for the fourth quarter of 2023 was a loss of $3.6 million compared with an operating loss of $6.7 million in Q3 of 2023 and an operating loss of $1.0 million in Q4 of 2022. Non-operating other income and expense and other items below the operating line for the fourth quarter of 2023 was a net loss of $62,000. The details can be seen in the P&L included in our press release today. For Q4 of 2023, we had a non-GAAP net loss of $2.8 million or $0.07 per share compared with a non-GAAP net loss of $4.9 million or $0.12 per share in the third quarter of 2023. Non-GAAP net income in Q4 2022 was $2.0 million or $0.05 per share. On a GAAP basis, net loss in Q4 was $3.6 million or $0.09 per share. By comparison, net loss was $5.8 million or $0.14 per share in the third quarter of 2023. GAAP net income in Q4 of 2022 was $1.3 million or $0.03 per share. The weighted average basic shares outstanding in Q4 of 2023 was $42.9 million. Cash, cash equivalents and investments were $52.3 million as of December 31, by comparison, at September 30, it was $43.6 million. Depreciation and amortization in the fourth quarter was $2.2 million and capital investments was about $4 million. Total stock comp was about $800,000. Net inventory was flat quarter-to-quarter. 38% of the inventory is raw materials and WIP is 58%. Finished goods makes up approximately 4%. This concludes the discussion of our quarterly financial results, turning to our plan to list our subsidiary, Tongmei in China on the star market in Shanghai, in regards to the Tongmei, we need to resolve 1 open item, although it is moving slower than we expected, we are making progress and are confident that Tongmei remain an excellent candidate for listing. With that, I'll now turn the call over to Dr. Morris Young for a review of our business and markets. Morris?